Overview

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Status:
Recruiting

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multinational, parallel 2-arm, randomized Phase 3 study evaluating the efficacy and safety of futibatinib versus gemcitabine-cisplatin chemotherapy as first-line treatment of patients with advanced, metastatic, or recurrent unresectable iCCA harboring FGFR2 gene rearrangements

Phase:

Phase 3

Details

Lead Sponsor:

Taiho Oncology, Inc.

Treatments:

Cisplatin
Futibatinib
Gemcitabine